Literature DB >> 10882301

Transcriptional regulation of type I receptor tyrosine kinases in the mammary gland.

N P Bates1, H C Hurst.   

Abstract

The transcriptional regulation of the human EGFR3 and ERBB2 genes has been extensively studied, particularly in the context of their overexpression in breast cancer. Here we summarize published work detailing the transcription factors which interact with the promoters of these and the rat ERBB2 homologue, neu, genes and discuss their possible relevance to gene activation in cancer. In addition we review the biologically significant molecules which modulate expression of these genes and discuss the nuclear factors involved in mediating these responses. We also describe novel therapies which may result from these studies and highlight directions for future research into the control of expression of the EGFR and ERBB2 genes in the normal mammary gland and in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10882301     DOI: 10.1023/a:1026303814855

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  79 in total

Review 1.  Nuclease hypersensitive sites in chromatin.

Authors:  D S Gross; W T Garrard
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

2.  A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma.

Authors:  J M Bosher; N F Totty; J J Hsuan; T Williams; H C Hurst
Journal:  Oncogene       Date:  1996-10-17       Impact factor: 9.867

3.  Positive and negative regulatory elements in the human erbB-2 gene promoter.

Authors:  Y Chen; G N Gill
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

4.  Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation.

Authors:  M Tal; C R King; M H Kraus; A Ullrich; J Schlessinger; D Givol
Journal:  Mol Cell Biol       Date:  1987-07       Impact factor: 4.272

5.  Strong association between c-myb and oestrogen-receptor expression in human breast cancer.

Authors:  M Guérin; Z M Sheng; N Andrieu; G Riou
Journal:  Oncogene       Date:  1990-01       Impact factor: 9.867

6.  The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma.

Authors:  J M Bosher; T Williams; H C Hurst
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

7.  Gene therapy for cancer using tumour-specific prodrug activation.

Authors:  J D Harris; A A Gutierrez; H C Hurst; K Sikora; N R Lemoine
Journal:  Gene Ther       Date:  1994-05       Impact factor: 5.250

8.  Phorbol ester or epidermal growth factor (EGF) stimulates the concurrent accumulation of mRNA for the EGF receptor and its ligand transforming growth factor-alpha in a breast cancer cell line.

Authors:  J D Bjorge; A J Paterson; J E Kudlow
Journal:  J Biol Chem       Date:  1989-03-05       Impact factor: 5.157

9.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

Authors:  H B Muss; A D Thor; D A Berry; T Kute; E T Liu; F Koerner; C T Cirrincione; D R Budman; W C Wood; M Barcos
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

10.  Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.

Authors:  C Wright; S Nicholson; B Angus; J R Sainsbury; J Farndon; J Cairns; A L Harris; C H Horne
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

View more
  8 in total

1.  Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression.

Authors:  Douglas Vernimmen; Dominique Begon; Christophe Salvador; Stéphanie Gofflot; Madeleine Grooteclaes; Rosita Winkler
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

Review 2.  Hormonal regulation of type I receptor tyrosine kinase expression in the mammary gland.

Authors:  M De Bortoli; C Dati
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

3.  HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".

Authors:  Javier A Menéndez; Alejandro Vázquez-Martín; Santiago Ropero; Ramón Colomer; Ruth Lupu
Journal:  Clin Transl Oncol       Date:  2006-11       Impact factor: 3.405

Review 4.  Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.

Authors:  D F Stern
Journal:  Breast Cancer Res       Date:  2000-03-25       Impact factor: 6.466

Review 5.  Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment.

Authors:  H C Hurst
Journal:  Breast Cancer Res       Date:  2001-10-01       Impact factor: 6.466

6.  Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells.

Authors:  Lisandra Negrón-Vega; Elsa M Cora; Marianela Pérez-Torres; Shou-Ching Tang; Nita J Maihle; Jung Su Ryu
Journal:  Biochem Biophys Rep       Date:  2022-08-19

7.  Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2.

Authors:  Bo-Wei Wang; Chih-Hao Huang; Liang-Chih Liu; Fang-Ju Cheng; Ya-Ling Wei; Yueh-Ming Lin; Yu-Fei Wang; Ching-Ting Wei; Yeh Chen; Yun-Ju Chen; Wei-Chien Huang
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

8.  Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers.

Authors:  D Vernimmen; M Gueders; S Pisvin; P Delvenne; R Winkler
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.